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Biological monitoring
Assays: (a) Bacterial mutagenicity (TA98, TA100), (b) sin-
gle cell gel electrophoresis (SCGE; endpoint: DNA migra-
tion) with primary rat hepatocytes. Waste water samples:
effluent of (a) the total hospital (TH), (b) the oncological
ward (OW), collected before dilution in the Vienna sewer
system.
Results
All samples negative in bacterial assays, acute bacterio-
cidal/bacteriostatic effects of highest water volumes
tested. SCGE assays:  increase but no significant differences
between DNA migration caused by TH and OW samples.
The genotoxic activities of the waters could be reduced sig-
nificantly (25–50%) by waste water treatment.
Risk assessment
according to EU Guidelines aimed at elucidating priorities
and urgencies for risk management. Integrating chemical
and biological monitoring data, genotoxic profile and
(sparse) data on aquatic toxicity revealed that the endan-
germent of humans, aquatic and terrestrial environment
by cytostatic drugs released via hospital waste water could
be preliminary classified as small. A reduction of the
avoidable environmental load – in line with EU docu-
ment 2000/60/EC – could be achieved by advanced waste
water treatment at the source as applied within the frame-
work of this project.
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